Satsuma Pharmaceuticals, Inc. Common Stock
STSA
STSA was delisted on the 7th of June, 2023.
31 hedge funds and large institutions have $12.7M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 6 closing their positions.
3% less funds holding
Funds holding: 32 → 31 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
28% less capital invested
Capital invested by funds: $17.6M → $12.7M (-$4.89M)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lion Point Capital
New York
|
+$294K |
| 2 |
Two Sigma Advisers
New York
|
+$112K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$46K |
| 4 |
FIA
FNY Investment Advisers
New York
|
+$42.5K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$16.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$735K |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$643K |
| 3 |
Millennium Management
New York
|
-$157K |
| 4 |
Renaissance Technologies
New York
|
-$82.4K |
| 5 |
CPIG
Chicago Partners Investment Group
Chicago,
Illinois
|
-$54.3K |
STSA Hedge Fund Activity: Q1 2023 in Review
31 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q1 2023, worth a combined $12.7M — down 28% from $17.6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of STSA and 5 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 6 added.
The largest buyer was Lion Point Capital, opening a new position worth an estimated $294K. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $735K sold.
- 31 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q1 2023, down from 32 in Q4 2022.
- Funds reported $12.7M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q1 2023, down 28% quarter-over-quarter.
- 5 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q1 2023 and 6 closed out, a net change of -1 holder.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q1 2023 was Lion Point Capital, an estimated $294K added.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q1 2023 was Driehaus Capital Management, an estimated $735K sold.
Based on aggregated 13F filings for Q1 2023.